(Q43545482)

English

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

scientific article published on 28 August 2008

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

Sharad A Ghamande

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Michael H Silverman

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Warner Huh

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Kian Behbakht

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Greg Ball

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Luceli Cuasay

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sidse O Würtz

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Nils Brunner

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Michael A Gold

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

28 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

89-94

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Use of tumour markers in monitoring the course of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

CA 125: the past and the future

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

CA125 response: can it replace the traditional response criteria in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.06.028

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.06.028

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43545482&oldid=2098222369"